SEARCH

SEARCH BY CITATION

References

  • 1
    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91: 1616-1634.
  • 2
    PROCRIT® (Epoetin alfa) [package insert]. Raritan, NJ: Ortho Biotech Products LP; August 2008.
  • 3
    EPOGEN® (Epoetin alfa) [package insert]. Thousand Oaks, CA: Amgen, Inc; August 2008.
  • 4
    Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther. 2006; 28: 801-831.
  • 5
    Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007; 11: 1-220.
  • 6
    Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of 4 observational studies. Clin Ther. 2006; 28: 1701-1708.
  • 7
    Henry DH, Gordan LN, Charu V, et al. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin. 2006; 22: 1403-1413.
  • 8
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist. 2004; 9: 90-96.
  • 9
    Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Support Care Cancer. 2007; 15: 1385-1392.
  • 10
    Steensma DP, Molina R, Sloan JA, et al. Phase III study of 2 different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol. 2006; 24: 1079-1089.
  • 11
    Mark TL, McKenzie RS, Fastenau J, Piech CT. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin. 2005; 21: 1347-1354.
  • 12
    ARANESP® (Darbepoetin alfa) [package insert]. Thousand Oaks, CA: Amgen, Inc; August 2008.
  • 13
    Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997; 13: 63-74.
  • 14
    Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004; 40: 2201-2216.
  • 15
    Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002; 100: 2303-2320.